Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Report Overview

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia, and general malaise. Treatment includes antiviral drugs.

The Influenza A Virus, H7N9 Subtype Infections pipeline drugs market research report provides comprehensive information on the Influenza A Virus, H7N9 Subtype Infections targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Influenza A Virus, H7N9 Subtype Infections targeted therapeutics development with respective active and dormant or discontinued projects.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Segmentation by Target

The key targets in the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market are Hemagglutinin, Exo Alpha Sialidase, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Neuraminidase A, and Polymerase Basic Protein 2 among others. Hemagglutinin was the target with the highest number of Influenza A Virus, H7N9 Subtype Infections drugs in development in 2022.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Target

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by TargetFor more target insights on Influenza A Virus, H7N9 Subtype Infections pipeline drugs market, download a free report sample

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market are Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, and Neuraminidase A Inhibitor among others. Exo Alpha Sialidase Inhibitor and Hemagglutinin Inhibitor led the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market in 2022.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Mechanisms of Action

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more MoA insights on the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market, download a free report sample

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market are intramuscular, oral, parenteral, inhalational, intralesional, intravenous, and nasal. Intramuscular and  oral are the most preferred RoA in the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Routes of Administration

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Routes of AdministrationFor more RoA insights on the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market, download a free report sample

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market are small molecule, inactivated vaccine, vaccine, DNA vaccine, recombinant protein, and subunit vaccine among others. Small molecule leads the pipeline drugs market in this segment.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Molecule Types

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Molecule TypesTo know more about molecule types in the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market, download a free report sample

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Influenza A Virus, H7N9 Subtype Infections pipeline drugs market are NanoViricides Inc, TaiGen Biotechnology Co Ltd, AIM ImmunoTech Inc, AusBio Ltd, Beijing Tiantan Biological Products Co Ltd, Celdara Medical LLC, and Cocrystal Pharma Inc among others.

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by Companies

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Analysis, by CompaniesTo know more about leading Influenza A Virus, H7N9 Subtype Infections pipeline drugs market players, download a free report sample

Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Overview

Key Target Hemagglutinin, Exo Alpha Sialidase, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Neuraminidase A, and Polymerase Basic Protein 2
Key Mechanisms of Action Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, and Neuraminidase A Inhibitor
Key Routes of Administration Intramuscular, Oral, Parenteral, Inhalational, Intralesional, Intravenous, and Nasal
Key Molecule Types Small Molecule, Inactivated Vaccine, Vaccine, DNA Vaccine, Recombinant Protein, and Subunit Vaccine
Leading Companies NanoViricides Inc, TaiGen Biotechnology Co Ltd, AIM ImmunoTech Inc, AusBio Ltd, Beijing Tiantan Biological Products Co Ltd, Celdara Medical LLC, and Cocrystal Pharma Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AIM ImmunoTech Inc
AusBio Ltd
Beijing Tiantan Biological Products Co Ltd
Celdara Medical LLC
Cocrystal Pharma Inc
Codagenix Inc
CSL Ltd
EpiVax Inc
Greffex Inc
GSK plc
Hualan Biological Bacterin Co Ltd
Inovio Pharmaceuticals Inc
Medicago Inc
NanoViricides Inc
New Amsterdam Sciences Inc
Ology Bioservices Inc
Pneumagen Ltd
TaiGen Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H7N9 Subtype Infections – Overview

Influenza A Virus, H7N9 Subtype Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H7N9 Subtype Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H7N9 Subtype Infections – Companies Involved in Therapeutics Development

AIM ImmunoTech Inc

AusBio Ltd

Beijing Tiantan Biological Products Co Ltd

Celdara Medical LLC

Cocrystal Pharma Inc

Codagenix Inc

CSL Ltd

EpiVax Inc

Greffex Inc

GSK plc

Hualan Biological Bacterin Co Ltd

Inovio Pharmaceuticals Inc

Medicago Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Ology Bioservices Inc

Pneumagen Ltd

TaiGen Biotechnology Co Ltd

Influenza A Virus, H7N9 Subtype Infections – Drug Profiles

CC-42344 – Drug Profile

Product Description

Mechanism Of Action

CDX-H7N9 – Drug Profile

Product Description

Mechanism Of Action

CMBT-1 – Drug Profile

Product Description

Mechanism Of Action

GSK-3206641A – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (monovalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (monovalent) vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (monovalent) vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (split virion) vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine – Drug Profile

Product Description

Mechanism Of Action

influenza [strains A/H7N9] (split virion) vaccine – Drug Profile

Product Description

Mechanism Of Action

interferon alfa-n3 – Drug Profile

Product Description

Mechanism Of Action

MD-2009 – Drug Profile

Product Description

Mechanism Of Action

MDG-7529 – Drug Profile

Product Description

Mechanism Of Action

NAS-911 – Drug Profile

Product Description

Mechanism Of Action

Neumifil – Drug Profile

Product Description

Mechanism Of Action

NVINF-1 – Drug Profile

Product Description

Mechanism Of Action

NVINF-2 – Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Influenza Virus Infections – Drug Profile

Product Description

Mechanism Of Action

TG-1000 – Drug Profile

Product Description

Mechanism Of Action

Influenza A Virus, H7N9 Subtype Infections – Dormant Projects

Influenza A Virus, H7N9 Subtype Infections – Discontinued Products

Influenza A Virus, H7N9 Subtype Infections – Product Development Milestones

Featured News & Press Releases

Jan 10, 2019: Development and Industrialization Construction Project of Quadrivalent Influenza Vaccine of Hualan Biological Bacterin

May 23, 2018: Application of Quadrivalent Influenza Vaccine (QIV)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by AIM ImmunoTech Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by AusBio Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Celdara Medical LLC, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Cocrystal Pharma Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Codagenix Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by CSL Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by EpiVax Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Greffex Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by GSK plc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Hualan Biological Bacterin Co Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Medicago Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by NanoViricides Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by New Amsterdam Sciences Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Ology Bioservices Inc, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Pneumagen Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections – Pipeline by TaiGen Biotechnology Co Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections – Dormant Projects, 2022

Influenza A Virus, H7N9 Subtype Infections – Dormant Projects, 2022 (Contd..1)

Influenza A Virus, H7N9 Subtype Infections – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.